SummaryRMgm-5268
|
||||||||||
*RMgm-5268| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption, Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 36403748 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Yuda M, Nishi T |
| Name Group/Department | Department of Medical Zoology |
| Name Institute | Mie University School of Medicine |
| City | Mie, Tsu |
| Country | Japan |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5268 |
| Principal name | P52/SPECT2 DKO parasites |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Not different from wild type |
| Sporozoite | From analysis of B9(-) parasites (Rmgm-5266) that have the same phenotype as P52(-) parasites: Normal numbers of motile salivary gland sporozoites are formed. While 30 wild-type sporozoites were sufficient to establish infection in all rats, Even 1 × 10 B9(-) sporozoites were insufficient to establish infection in all rats. |
| Liver stage | From analysis of B9(-) parasites (Rmgm-5266) that have the same phenotype as P52(-) parasites: B9(-) parasites formed abnormal liver stages (LS) and displayed increased cell traversal activity. The number of B9(-) LS parasites formed in HepG2 cells was 6% that of wild-type parasites at 24 and 48 h post-inoculation (hpi) of sporozoites. The average diameter of the B9(-) LS parasites decreased to approximately 80 % that of wild-type LSs at 48 hpi. There was a decreased number of sporozoites entering the hepatocytes by productive invasion and reciprocally, an increased number of sporozoites that continued migration through the hepatocytes. Evidence is presented that B9(-) LS parasites develop in the nucleus of hepatocytes. From analysis of B9/SPECT2 DKO parasites (RMgm-5267) that have the same phenotype as P52/SPECT2 DKO parasites: With t he disruption of SPECT2 in B9(-) parasites, the cell traversal activity of sporozoites disappeared. In HepG2 cell culture no LSs of B9/SPECT2 DKO parasites were identified using fluorescence microscopy, demonstrating that all LS parasites inside the nucleus 5 were derived from sporozoites that invaded Hep G2 cells for cell traversal. Sporozoites in side these cells were still observed in B9 SPECT 2 DKO parasites and the number increased following SPECT2 disruption to a level similar to that of wild type. This result means that sporozoites lacking both cell invasion modes still enter ed HepG2 cells. |
| Additional remarks phenotype | Mutant/mutation Protein (function) The spect2/pplp1 gene is a member of a small, conserved family of proteins encoding perforin-like proteins containing membrane-attack complex/perforin domains (MACPF). The P. berghei genome contains 5 PLP proteins. SPECT2/PPLP1 is specifically expressed in salivary gland sporozoites (not in midgut sporozoites) and has a micronemal location (micronemes) Additional information From the paper analysing B9(-) parasites (RMgm-5266): We also performed cell wounding and membrane repair assays to evaluate the cell traversal activity of B9(-) sporozoites . The number of HepG2 cells damaged by invasion of B9(-) sporozoites was approximately 3 fold higher than that of wild type parasites. These results suggest that the disruption of B9 impaired the switching capacity of sporozoites . More specifically, there was a decreased number of sporozoites entering the hepatocytes by productive invasion and reciprocally, an increased number of sporozoites that continued migration through the hepatocytes . This phenotype of B9(-). is similar to the previously reported phenotypes of P52 disrupted P52(-) and P36 disrupted P36(-) parasites |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1002200 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0404500 | ||||||||||||||||||||||||
| Gene product | 6-cysteine protein P52 | ||||||||||||||||||||||||
| Gene product: Alternative name | P36p; Pb36p; P52 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||||||||
| Promoter of the selectable marker | unknown | ||||||||||||||||||||||||
| Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | P52(-)GFP parasites were generated by insertion of a GFP expression cassette into the B9 gene locus of wild-type parasites by homologous recombination. P52(-)GFP parasites were sorted using flow cytometry. The selected parasites were further separated from wild-type parasites by limiting dilution. Double knockout parasites were prepared from these parasites by additional disruption of SPECT2 using a pyrimethamine-resistant gene as a selectable marker. | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1006300 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0408700 | ||||||||||||||||||||||||
| Gene product | perforin-like protein 1 | sporozoite micronemal protein essential for cell traversal | ||||||||||||||||||||||||
| Gene product: Alternative name | PLP1; PPLP1, SPECT2 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | DD | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | pbdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | P52(-)GFP parasites were generated by insertion of a GFP expression cassette into the B9 gene locus of wild-type parasites by homologous recombination. P52(-)GFP parasites were sorted using flow cytometry. The selected parasites were further separated from wild-type parasites by limiting dilution. Double knockout parasites were prepared from these parasites by additional disruption of SPECT2 using a pyrimethamine-resistant gene as a selectable marker. | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||